Most corporate-governance work at a startup is documentation, not litigation — until the documentation is missing. A board written consent and a stockholder written consent are not ceremonial paperwork; they are the records that fix what the company decided, by whom, and on what authority. When those records are absent, the gap does not stay hidden: it surfaces at the worst time, in diligence on a financing or an acquisition, and it becomes discoverable. In KT4 Partners LLC v. Palantir Technologies, Inc., the Delaware Supreme Court held that where a company fails to keep formal board-level records, its emails and other electronic communications can become the necessary books-and-records evidence a stockholder is entitled to inspect under DGCL § 220 — the informal record becomes the operative one. This guide covers the two sides of that story: why clean consents are company-protective hygiene, and how Delaware's § 204 ratification of defective corporate acts cures the gaps when they are found. If you are reviewing executed documents, the Board Ratifying Consent Review Checklist and the Stockholder Ratifying Consent Review Checklist track each requirement with its force level and citations, and the ratifying-consent templates give you drafting starting points.
Why do board and stockholder consents matter — beyond formality?
A written consent's job is to memorialize the action actually approved — not to transcribe the discussion. Under DGCL § 141(f) the board may act without a meeting only on the unanimous written consent of all directors, and that consent must be filed with the minutes of the board's proceedings. That filing is the point: a clean, contemporaneous record of the decision is what lets the company show, later, that an act was authorized. The alternative is the KT4 v. Palantir problem — when the formal record is missing, a stockholder's § 220 books-and-records demand reaches into emails and chat to reconstruct what happened, and diffuse informal communications become the company's operative narrative. Concise formal consents are company-protective hygiene, and they are cheaper than the discovery fight their absence invites .
The discipline is to keep the record concise and action-focused. A consent should state what was approved and the authority for it; it should not read like a transcript, because over-detailed minutes create their own privilege and litigation problems. The § 141(f) filing-with-minutes requirement frames the duty, and § 220 supplies the stakes: the records a company keeps are the records it can rely on, and the ones it fails to keep are the ones a counterparty gets to reconstruct from email .
Treat every material board and stockholder action as something to paper contemporaneously, not to reconstruct at diligence. The cost of a clean consent is minutes; the cost of a missing one is a § 220 demand that turns your inbox into the company record. This is the first-principles reason the consents exist — not legacy formalism .
Sources for this answer
Primary law
A.2 8 Del. C. § 141(f)The board may act without a meeting only on the unanimous written consent of all directors — the mechanism behind a board written consent.
any action required or permitted to be taken at any meeting of the board of directors or of any committee thereof may be taken without a meeting if all members of the board or committee, as the case may be, consent thereto in writing, or by electronic transmission
See 8 Del. C. § 141(f).
Primary law
A.1 8 Del. C. § 141(f) (filing with the minutes)After a written-consent action is taken, the consent must be filed with the minutes of the board's proceedings — the contemporaneous record that a § 220 demand would otherwise reconstruct from email.
After an action is taken, the consent or consents relating thereto shall be filed with the minutes of the proceedings of the board of directors, or the committee thereof, in the same paper or electronic form as the minutes are maintained.
See 8 Del. C. § 141(f).
Diligence found an act no one properly authorized. What now?
Delaware supplies a statutory self-help remedy: § 204 ratification of defective corporate acts. A defective corporate act is one that is void or voidable solely as a result of a failure of authorization — shares issued without board approval, an option pool that overran the authorized reserve, a director elected without the required vote. The board cures it by adopting resolutions that name each act, its date, any putative shares, and the nature of the failure of authorization, and then approve the ratification. The boundary matters: § 204 cannot manufacture an act that was never taken, revive an act that was affirmatively rejected, or cure an act that is void for substantive illegality rather than a procedural authorization gap. For those, the fallback is a § 205 petition to the Court of Chancery, which has exclusive jurisdiction to validate.
The recitals are not boilerplate. A generic the Board ratifies any and all prior acts fails § 204(b)(1): the statute requires the specific act, its date, the number and type of any putative shares, and the failure of authorization, followed by the board's express approval of the ratification itself. And the ratifying consent must be adopted by a board that is validly in office — if the board's own composition is the defect diligence found, the cure has to be sequenced so the ratifying instrument is not itself defective .
Ratify specifically, not generically. Any and all prior acts ratifies nothing a court can test. Name each defective act, its date, the putative shares, and exactly what failed — issued without board approval, exceeded the authorized reserve, filed without the required stockholder vote — because § 204 only reaches acts void or voidable solely for a failure of authorization, and the record has to show the act is within the statute .
Sources for this answer
Primary law
B.1 8 Del. C. § 204(a)Section 204 cures a defective corporate act or putative stock only where it is void or voidable solely as a result of a failure of authorization — the boundary of the remedy, with § 205 as the fallback.
no defective corporate act or putative stock shall be void or voidable solely as a result of a failure of authorization if ratified as provided in this section
See 8 Del. C. § 204(a).
Primary law
B.2 8 Del. C. § 204(b)(1)(A)The board's ratifying resolutions must state the specific defective corporate act(s) to be ratified — a generic ratification fails the statute.
The defective corporate act or acts to be ratified;
See 8 Del. C. § 204(b)(1)(A).
Primary law
B.3 8 Del. C. § 204(b)(1)(E)The resolutions must state that the board approves the ratification — the operative approval, distinct from approving the underlying act.
That the board of directors approves the ratification of the defective corporate act or acts.
See 8 Del. C. § 204(b)(1)(E).
When do stockholders have to approve — and what's the voting trap?
Where the defective act would itself have required a stockholder vote — or resulted from a § 203 failure — § 204(c) requires the board's ratification to be submitted to stockholders, ordinarily by written consent under § 228 for a closely held company. Two rules trip people up. First, the voting denominator is current law: the quorum and voting requirements are those applicable to the type of act at the time of ratification, not the historic cap table. Second — the trap — the very putative shares being cured do not vote: § 204(d) provides that putative stock as of the board's adoption of the ratifying resolutions is neither entitled to vote nor counted for quorum. The shares whose validity is in question cannot supply the approval that would validate them .
Notice is the other half. Even when no stockholder vote is required, § 204(g) requires prompt notice of the ratification to all holders of valid and putative stock — including nonvoting holders and holders as of the time of the defective act — and that notice starts a 120-day clock within which any challenge must be brought. A current stockholders only distribution misses the statutory reach, and a missing notice never starts the repose clock, leaving the cure open to challenge. Where the cure requires a Delaware filing (a charter amendment, an authorized-share increase), a certificate of validation under § 204(e) must be filed before the ratification is effective as to that act .
Compute the approval percentage without the putative shares, and send the § 204(g) notice to more people than your current voting cap table — nonvoting holders and holders as of the defective-act time are entitled to it. These two moves — the excluded putative stock and the over-inclusive notice — are the most common § 204 stockholder-side errors, and each independently sinks the cure .
Sources for this answer
Primary law
C.1 8 Del. C. § 204(d)(5)Putative stock as of the board's adoption of the ratifying resolutions is neither entitled to vote nor counted for quorum in the vote to ratify — the shares being cured cannot vote on their own cure.
shall neither be entitled to vote nor counted for quorum purposes in any vote to ratify any defective corporate act.
See 8 Del. C. § 204(d)(5).
Primary law
C.2 8 Del. C. § 204(g)Prompt notice of the ratification must be given to all holders of valid and putative stock, whether voting or nonvoting — mandatory even when no stockholder vote is required.
prompt notice of the ratification shall be given to all holders of valid stock and putative stock, whether voting or nonvoting
See 8 Del. C. § 204(g).